Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IV Open-Label Clinical Trial to Evaluate the Efficacy of Ikervis on Clinical Parameters and Molecular/Cellular Biomarkers in Dry Eye Patients with Severe Keratitis who have not improved despite regular use of tear substitutes before and after Exposure to an Adverse Controlled Environment

Next Previous
Trial Profile

A Phase IV Open-Label Clinical Trial to Evaluate the Efficacy of Ikervis on Clinical Parameters and Molecular/Cellular Biomarkers in Dry Eye Patients with Severe Keratitis who have not improved despite regular use of tear substitutes before and after Exposure to an Adverse Controlled Environment

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 17 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ciclosporin (Primary)
  • Indications Dry eyes; Keratitis
  • Focus Therapeutic Use

Most Recent Events

  • 20 Apr 2021 Status changed from recruiting to completed.
  • 27 Jul 2020 Planned End Date changed to 1 Aug 2020.
  • 27 Jul 2020 Planned primary completion date changed to 1 Aug 2020.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top